Marshall Wace, LLP Heron Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,761,051 shares of HRTX stock, worth $3.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,761,051
Previous 494,354
256.23%
Holding current value
$3.5 Million
Previous $1.37 Million
350.18%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding HRTX
# of Institutions
198Shares Held
129MCall Options Held
94.7KPut Options Held
148K-
Rubric Capital Management LP New York, NY26.7MShares$53.2 Million2.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.62MShares$17.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$16.6 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.6MShares$15.1 Million0.05% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$13.9 Million58.47% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $236M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...